Icon Plc $ICLR Shares Sold by Live Oak Private Wealth LLC

Live Oak Private Wealth LLC reduced its stake in shares of Icon Plc (NASDAQ:ICLR) by 22.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,161 shares of the medical research company’s stock after selling 4,661 shares during the quarter. Live Oak Private Wealth LLC’s holdings in Icon were worth $2,807,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. EFG International AG bought a new stake in shares of Icon during the 4th quarter worth about $27,000. Abound Financial LLC bought a new position in shares of Icon in the fourth quarter valued at approximately $54,000. GAMMA Investing LLC increased its stake in shares of Icon by 21.4% during the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after acquiring an additional 69 shares during the period. Johnson Financial Group Inc. bought a new stake in Icon during the third quarter worth approximately $71,000. Finally, Blue Trust Inc. raised its holdings in Icon by 207.5% during the first quarter. Blue Trust Inc. now owns 658 shares of the medical research company’s stock worth $73,000 after purchasing an additional 444 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Insider Transactions at Icon

In other Icon news, Director Eugene Pacelli Mccague sold 841 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total value of $138,167.89. Following the completion of the transaction, the director directly owned 3,811 shares in the company, valued at $626,109.19. This trade represents a 18.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Anne Clem Whitaker sold 841 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89. Following the completion of the transaction, the director owned 891 shares of the company’s stock, valued at approximately $146,382.39. The trade was a 48.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 9,531 shares of company stock worth $1,565,764 in the last three months. Insiders own 44.00% of the company’s stock.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $161.40 on Wednesday. The company has a market capitalization of $12.36 billion, a PE ratio of 37.89, a price-to-earnings-growth ratio of 6.83 and a beta of 1.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. The stock has a fifty day moving average of $168.06 and a 200-day moving average of $134.25. Icon Plc has a one year low of $66.57 and a one year high of $203.91.

Icon (NASDAQ:ICLR) last issued its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The business had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. During the same period in the previous year, the firm posted $3.26 EPS. The company’s quarterly revenue was up 2.3% on a year-over-year basis. As a group, equities analysts anticipate that Icon Plc will post 9.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on ICLR shares. Robert W. Baird set a $194.00 price target on Icon in a research note on Friday, July 31st. Leerink Partners set a $145.00 price objective on Icon in a report on Thursday, May 28th. William Blair raised Icon to a “strong-buy” rating in a research note on Thursday, July 30th. UBS Group set a $160.00 target price on Icon in a report on Wednesday, June 24th. Finally, Piper Sandler cut shares of Icon to a “neutral” rating in a research report on Thursday, May 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Icon has a consensus rating of “Hold” and a consensus price target of $170.40.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.